盛夏方程式2049

无

[盛夏方程式2049 @PointNemo2049]

@HOThomasWPhelps Abdakibart from $AVTX ？IL-1b

[盛夏方程式2049 @PointNemo2049]

@andrewpannu Please send me the full report, thanks!

[Andrew Pannu @andrewpannu]

Sample of clinical PROTACs in the degrader landscape

In advance of a bigger report on the space we're dropping tomorrow, some key takeaways from the space:

• Of the 53 clinical-stage oncology PROTACs with a https://t.co/ZKRHLP1b3Q reference (from 37 unique sponsors), 85% are in Phase 1 or 1/2. This is a classic wide + shallow space

• The latest stage assets target ER, AR, BTK and KRAS G12D. The first 3 build on established treatment markets, with an angle to pick up patients with resistance to existing drugs. The last one represents where the space wants to go: can degradation can produce a targeted therapy where none is approved today?

• Chinese-origin companies account for ~40% of this sample and 3/4 of the Ph2 programs. Meanwhile all 3 Ph3 programs have big Pharma involvement, as well as ~25% of programs overall

Look out for the full report tomorrow!

[盛夏方程式2049 @PointNemo2049]

@KhalidAlNumi yes

[盛夏方程式2049 @PointNemo2049]

@andrewpannu hi-res version,please!

[盛夏方程式2049 @PointNemo2049]

@ZaraAi56190 Yes

[盛夏方程式2049 @PointNemo2049]

@Rashid971x @grok

[盛夏方程式2049 @PointNemo2049]

@andrewpannu RNA

[盛夏方程式2049 @PointNemo2049]

@andrewpannu TCE!

[Divya Tripathi @Divya_Tripa23]

2 Minutes Hand Mudras for Healthy Organs 👇

[盛夏方程式2049 @PointNemo2049]

@andrewpannu Great! Would you send me hi-res?😃

[盛夏方程式2049 @PointNemo2049]

@andrewpannu Sleuth

[盛夏方程式2049 @PointNemo2049]

@andrewpannu Sleuth

[Hidehito HORINOUCHI @HHorinouchi]

🔥Acquired resistance to daraxonrasib (RAS(ON) inhibitor) guides combination strategies in PDAC
🆙 @NatureMedicine
🎯ctDNA profiling of 44 PDAC pts; RAS pathway alterations in 59% — KRAS amp most frequent (36%)
🎯Daraxonrasib + T-DXd, amivantamab, or RAS(ON) inhibitor doublet (+ zoldonrasib) avert resistance in preclinical models
🎙Dr. Ida Aronchik & Dr. Sumit Kar
@OncoAlert @Larvol @KRASKickers
https://t.co/lhvC9nocJQ

[盛夏方程式2049 @PointNemo2049]

@raffcolo @JacobPlieth yes, MediLink Tx is a Chinese biotech.🤣Mablink bio is from France.

[盛夏方程式2049 @PointNemo2049]

@JacobPlieth @raffcolo It's my pleasure.

[盛夏方程式2049 @PointNemo2049]

@JacobPlieth @raffcolo Mablink is just another story. The founders are from SKB Bio, which licensed the sac-TMT(TROP2) to Merck. Mablink team optimized the linker-payload and generated multiple assets. They have completed a lot of deals, such as Roche, ZLAB, Helius etc. So you can see many YL0014s

[盛夏方程式2049 @PointNemo2049]

@JacobPlieth @raffcolo Warheads are all from Mabcare. CDH6 mab of CUSP06（AMT-707） is from Multitude and the ADC is also generated by Multitude. OnCusp licensed the global rights of AMT-707 except China right from Multitude in 2022. CUSP06 is second-in-class and potential best-in-class.

[盛夏方程式2049 @PointNemo2049]

@raffcolo @JacobPlieth Don't mention it😁

[盛夏方程式2049 @PointNemo2049]

@JacobPlieth @raffcolo No problem😀